Jean-François Rax
Director/Board Member en BIOSENIC SA .
Perfil
Jean-François Rax is currently an Investment Director at Capital Grand Est SAS.
He also holds director positions at Anagenesis Biotechnologies SAS, Urania Therapeutics SAS, and is a Non-Executive Director at BioSenic SA. Additionally, he is a Member-Supervisory Board at Emosis SAS.
Previously, he was a Director at Bionext SA and a Business Analyst at INSERM Transfert SA from 2011 to 2014.
He was also a Member-Supervisory Board at Inoviem Scientific SAS.
Mr. Rax obtained his undergraduate degree from Institut National des Sciences Appliquées de Lyon.
Cargos activos de Jean-François Rax
Empresas | Cargo | Inicio |
---|---|---|
BIOSENIC SA | Director/Board Member | - |
Capital Grand Est SAS
Capital Grand Est SAS Investment ManagersFinance Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France. | Private Equity Analyst | 01/04/2014 |
Emosis SAS
Emosis SAS Miscellaneous Commercial ServicesCommercial Services Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France. | Director/Board Member | - |
Anagenesis Biotechnologies SAS
Anagenesis Biotechnologies SAS Medical/Nursing ServicesHealth Services Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France. | Director/Board Member | - |
Urania Therapeutics SAS
Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Director/Board Member | - |
Antiguos cargos conocidos de Jean-François Rax.
Empresas | Cargo | Fin |
---|---|---|
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France. | Private Equity Analyst | 01/03/2014 |
Bionext SA
Bionext SA Packaged SoftwareTechnology Services Bionext SA develops software applications for pharmaceuticals and biotechnology companies. The firm integrates big data and cloud computing, and OMICS data through computer simulations for enabling to visualize, understand, and correct actions of drugs in human cells, as well as in drug discovery processes. The company was founded by Laurent-Philippe Albou and Serge Henri Albou in 2009 and is headquartered in Strasbourg, France. | Director/Board Member | - |
Inoviem Scientific SAS
Inoviem Scientific SAS BiotechnologyHealth Technology Inoviem Scientific SAS offers preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Its services include preclinical and drug discovery, patient stratification and biomarkers clinical development. The company was founded by Pierre Eftekhari in 2011 and is headquartered in Strasbourg, France. | Director/Board Member | - |
Formación de Jean-François Rax.
Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BIOSENIC SA | Health Technology |
Empresas privadas | 7 |
---|---|
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France. | Finance |
Capital Grand Est SAS
Capital Grand Est SAS Investment ManagersFinance Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France. | Finance |
Bionext SA
Bionext SA Packaged SoftwareTechnology Services Bionext SA develops software applications for pharmaceuticals and biotechnology companies. The firm integrates big data and cloud computing, and OMICS data through computer simulations for enabling to visualize, understand, and correct actions of drugs in human cells, as well as in drug discovery processes. The company was founded by Laurent-Philippe Albou and Serge Henri Albou in 2009 and is headquartered in Strasbourg, France. | Technology Services |
Inoviem Scientific SAS
Inoviem Scientific SAS BiotechnologyHealth Technology Inoviem Scientific SAS offers preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Its services include preclinical and drug discovery, patient stratification and biomarkers clinical development. The company was founded by Pierre Eftekhari in 2011 and is headquartered in Strasbourg, France. | Health Technology |
Anagenesis Biotechnologies SAS
Anagenesis Biotechnologies SAS Medical/Nursing ServicesHealth Services Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France. | Health Services |
Emosis SAS
Emosis SAS Miscellaneous Commercial ServicesCommercial Services Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France. | Commercial Services |
Urania Therapeutics SAS
Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |
- Bolsa de valores
- Insiders
- Jean-François Rax